MétaCan
Menu
Back to cohort

S1419 The Effect of Race on Treatment Response to Terlipressin in Patients with Hepatorenal Syndrome: A Pooled Analysis of 3 Phase III Clinical Studies

2023· article· en· W4387734318 on OpenAlexaboutno aff
Paul J. Thuluvath, Nikolaos Pyrsopoulos, Kalyan Ram Bhamidimarri, Nicholas Lim, Khurram Jamil

Bibliographic record

VenueThe American Journal of Gastroenterology · 2023
Typearticle
Languageen
FieldMedicine
TopicElectrolyte and hormonal disorders
Canadian institutionsnot available
Fundersnot available
KeywordsTerlipressinMedicineHepatorenal syndromeInternal medicinePlaceboRenal functionUnivariate analysisGastroenterologyCreatinineCirrhosisMultivariate analysisPathology

Abstract

fetched live from OpenAlex

Introduction: Owing to its ability to reverse hepatorenal syndrome (HRS)—a form of acute kidney injury—terlipressin is recommended (in combination with albumin) as a first-line therapy for adult patients with HRS. The efficacy and safety of terlipressin treatment for patients with HRS has been examined in 3 placebo-controlled North American Phase III clinical studies. Notably, across these clinical studies, most patients were White. Therefore, this study used a pooled dataset of patients with HRS to examine whether there is any impact of race (White vs non-White) on treatment response to terlipressin. Methods: The pooled intent-to-treat dataset included data from 3 clinical studies (ie, OT-0401, REVERSE, and CONFIRM) that examined terlipressin treatment in adult patients with HRS, defined as a rapidly progressive worsening of kidney function to a serum creatine (SCr) ≥ 2.25 mg/dL (CONFIRM) or ≥ 2.5 mg/dL (OT-0401 and REVERSE). HRS reversal, defined as the proportion of patients achieving a SCr level of ≤ 1.5 mg/dL while on treatment, including up to 24 hours after the last dose of study drug, was examined by race (ie, White vs non-White). Race was assessed for the potential to predict treatment response (ie, HRS reversal) by univariate logistic regression analysis. Results: These 3 clinical studies were conducted at large tertiary centers in the US and Canada and enrolled 608 patients in total. Most patients evaluable for the race group (n = 603) were White (terlipressin, 313/348 [89.9%]; placebo, 235/255 [92.2%]). Among White patients (n = 548), more patients achieved HRS reversal with terlipressin than with placebo (34.5% vs 17.0%; P < .001). Similarly, among non-White patients (n = 55), more patients achieved HRS reversal with terlipressin (22.9%) than with placebo (10.0%); however, statistical significance was not reached (P = .297) (Table 1). Race (White vs non-White) was not significantly associated with HRS reversal (odds ratio [95% CI]: terlipressin, 1.778 [0.781 – 4.048], P = .170; placebo, 1.846 [0.412 – 8.273], P = .423). Conclusion: Race was not significantly associated with the odds of achieving HRS reversal for patients in the terlipressin group. Therefore, race is unlikely to influence the clinical response to terlipressin treatment among patients with HRS. Table 1. - Incidence of HRS reversal by race HRS reversal, n/N (%) Terlipressin Placebo P valuea White 108/313 (34.5) 40/235 (17.0) <.001 Non-White 8/35 (22.9) 2/20 (10.0) .297 aFrom a Chi-square/Fisher’s exact test. HRS, hepatorenal syndrome.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.382
Threshold uncertainty score0.276

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.356
Teacher spread0.342 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of GastroenterologySame topicElectrolyte and hormonal disordersFrench-language works237,207